ARQT
Price
$8.47
Change
-$0.12 (-1.40%)
Updated
Apr 26, 6:59 PM EST
4 days until earnings call
BEAM
Price
$21.38
Change
-$0.22 (-1.02%)
Updated
Apr 26, 6:59 PM EST
9 days until earnings call
Ad is loading...

Analysis and predictions ARQT vs BEAM

Header iconARQT vs BEAM Comparison
Open Charts ARQT vs BEAMBanner chart's image
Arcutis Biotherapeutics
Price$8.47
Change-$0.12 (-1.40%)
Volume$1.39M
CapitalizationN/A
Beam Therapeutics
Price$21.38
Change-$0.22 (-1.02%)
Volume$713.48K
CapitalizationN/A
View a ticker or compare two or three
ARQT vs BEAM Comparison Chart

Loading...

ARQTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BEAMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
ARQT vs. BEAM commentary
Apr 28, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a StrongSell and BEAM is a Hold.

COMPARISON
Comparison
Apr 28, 2024
Stock price -- (ARQT: $8.47 vs. BEAM: $21.38)
Brand notoriety: ARQT and BEAM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 57% vs. BEAM: 80%
Market capitalization -- ARQT: $973.81M vs. BEAM: $1.76B
ARQT [@Biotechnology] is valued at $973.81M. BEAM’s [@Biotechnology] market capitalization is $1.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $568.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • BEAM’s FA Score: 1 green, 4 red.
According to our system of comparison, BEAM is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 3 TA indicator(s) are bullish while BEAM’s TA Score has 2 bullish TA indicator(s).

  • ARQT’s TA Score: 3 bullish, 7 bearish.
  • BEAM’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, BEAM is a better buy in the short-term than ARQT.

Price Growth

ARQT (@Biotechnology) experienced а -6.92% price change this week, while BEAM (@Biotechnology) price change was -10.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.69%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +1262.42%.

Reported Earning Dates

ARQT is expected to report earnings on Aug 01, 2024.

BEAM is expected to report earnings on Aug 06, 2024.

Industries' Descriptions

@Biotechnology (+1.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for ARQT with price predictions.
OPEN
A.I.dvisor published
a Summary for BEAM with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BEAM($1.76B) has a higher market cap than ARQT($974M). ARQT YTD gains are higher at: 162.229 vs. BEAM (-21.455).
ARQTBEAMARQT / BEAM
Capitalization974M1.76B55%
EBITDAN/AN/A-
Gain YTD162.229-21.455-756%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
ARQTBEAM
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 11 days ago
83%
N/A
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
ARQTDaily Signal changed days agoGain/Loss if shorted
 
Show more...
BEAMDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JAGDX10.450.07
+0.67%
Janus Henderson Adaptive Global Allc D
WLCIX14.110.05
+0.36%
Allspring Large Company Value Inst
IMORX17.410.05
+0.29%
Voya MidCap Opportunities R
ACESX10.560.03
+0.28%
Invesco Equity and Income R
VSCRX52.440.08
+0.15%
Virtus KAR Small-Cap Core R6

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with MLYS. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then MLYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
-1.40%
MLYS - ARQT
40%
Loosely correlated
+7.52%
PRME - ARQT
40%
Loosely correlated
+2.91%
SANA - ARQT
39%
Loosely correlated
+2.59%
BEAM - ARQT
38%
Loosely correlated
-1.02%
GBIO - ARQT
38%
Loosely correlated
-3.65%
More